{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,10]],"date-time":"2026-01-10T03:03:32Z","timestamp":1768014212076,"version":"3.49.0"},"reference-count":40,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2018,1]]},"abstract":"<jats:sec>\n            <jats:title>Background:<\/jats:title>\n            <jats:p>The World Health Organization recommended increased dosages of the first-line antituberculosis (anti-TB) drugs for children in 2010. We examined the frequency of and factors associated with low plasma maximum concentration (C<jats:sub>max<\/jats:sub>) of each drug in children treated with the revised dosages.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods:<\/jats:title>\n            <jats:p>Children on anti-TB therapy for at least 4 weeks underwent pharmacokinetic testing. Plasma C<jats:sub>max<\/jats:sub> below the lower limit of proposed reference range was considered low. Bivariate and multivariate analyses were used to examine the factors associated with low C<jats:sub>max<\/jats:sub> of each drug.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results:<\/jats:title>\n            <jats:p>Of the 100 children, 58% were male, 50% HIV-infected and 49% younger than 5 years old. The median (interquartile range) C<jats:sub>max<\/jats:sub> was 5.9 (4.5\u20137.7) \u00b5g\/mL for isoniazid, 6.5 (4.9\u20138.8) \u00b5g\/mL for rifampin, 26.0 (21.2\u201333.4) \u00b5g\/mL for pyrazinamide and 1.7 (0.9\u20132.7) \u00b5g\/mL for ethambutol. There was a strong correlation between C<jats:sub>max<\/jats:sub> and AUC<jats:sub>0-8h<\/jats:sub> for all drugs. Low C<jats:sub>max<\/jats:sub> occurred in 9\/100 (9.0%), 61\/100 (61.0%), 17\/97 (17.5%) and 60\/97 (61.9%) for isoniazid, rifampin, pyrazinamide and ethambutol, respectively. In addition, 75\/97 (77.3%) children had pyrazinamide C<jats:sub>max<\/jats:sub> &lt; 35 \u00b5g\/mL. Factors associated with low C<jats:sub>max<\/jats:sub> were NAT2 metabolizer phenotype status for isoniazid; height, dosage and HIV coinfection status for rifampin; height for pyrazinamide; and age, dosage and HIV coinfection status for ethambutol.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions:<\/jats:title>\n            <jats:p>The high frequency of low rifampin and ethambutol C<jats:sub>max<\/jats:sub> in our study is consistent with emerging pharmacokinetic data in children treated according to the new WHO recommendations. Higher dosages than currently recommended especially for rifampin may be necessary in children.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/inf.0000000000001687","type":"journal-article","created":{"date-parts":[[2017,7,18]],"date-time":"2017-07-18T17:23:33Z","timestamp":1500398613000},"page":"43-51","source":"Crossref","is-referenced-by-count":15,"title":["Evaluation of the Adequacy of the 2010 Revised World Health Organization Recommended Dosages of the First-line Antituberculosis Drugs for Children"],"prefix":"10.1097","volume":"37","author":[{"given":"Hongmei","family":"Yang","sequence":"first","affiliation":[{"name":"Department of Medicine, College of Medicine and Emerging Pathogens Institute, University of Florida, Gainesville, FL."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anthony","family":"Enimil","sequence":"additional","affiliation":[{"name":"Department of Medicine, College of Medicine and Emerging Pathogens Institute, University of Florida, Gainesville, FL."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fizza S.","family":"Gillani","sequence":"additional","affiliation":[{"name":"Department of Medicine, College of Medicine and Emerging Pathogens Institute, University of Florida, Gainesville, FL."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sampson","family":"Antwi","sequence":"additional","affiliation":[{"name":"Department of Medicine, College of Medicine and Emerging Pathogens Institute, University of Florida, Gainesville, FL."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Albert","family":"Dompreh","sequence":"additional","affiliation":[{"name":"Department of Medicine, College of Medicine and Emerging Pathogens Institute, University of Florida, Gainesville, FL."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Antoinette","family":"Ortsin","sequence":"additional","affiliation":[{"name":"Department of Medicine, College of Medicine and Emerging Pathogens Institute, University of Florida, Gainesville, FL."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eugene","family":"Adu Awhireng","sequence":"additional","affiliation":[{"name":"Department of Medicine, College of Medicine and Emerging Pathogens Institute, University of Florida, Gainesville, FL."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maxwell","family":"Owusu","sequence":"additional","affiliation":[{"name":"Department of Medicine, College of Medicine and Emerging Pathogens Institute, University of Florida, Gainesville, FL."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lubbe","family":"Wiesner","sequence":"additional","affiliation":[{"name":"Department of Medicine, College of Medicine and Emerging Pathogens Institute, University of Florida, Gainesville, FL."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Charles A.","family":"Peloquin","sequence":"additional","affiliation":[{"name":"Department of Medicine, College of Medicine and Emerging Pathogens Institute, University of Florida, Gainesville, FL."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Awewura","family":"Kwara","sequence":"additional","affiliation":[{"name":"Department of Medicine, College of Medicine and Emerging Pathogens Institute, University of Florida, Gainesville, FL."}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-20230913","doi-asserted-by":"crossref","first-page":"794","DOI":"10.5588\/ijtld.12.0567","article-title":"Requirements for the clinical evaluation of new anti-tuberculosis agents in children.","volume":"17","author":"Donald","year":"2013","journal-title":"Int J Tuberc Lung Dis"},{"key":"R2-20230913","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1002\/cpt.164","article-title":"Antituberculosis drugs in children.","volume":"98","author":"Schaaf","year":"2015","journal-title":"Clin Pharmacol Ther"},{"key":"R3-20230913","doi-asserted-by":"crossref","first-page":"3197","DOI":"10.1128\/AAC.01681-08","article-title":"Pharmacokinetics-pharmacodynamics of pyrazinamide in a novel in vitro model of tuberculosis for sterilizing effect: a paradigm for faster assessment of new antituberculosis drugs.","volume":"53","author":"Gumbo","year":"2009","journal-title":"Antimicrob Agents Chemother"},{"key":"R4-20230913","doi-asserted-by":"crossref","first-page":"3781","DOI":"10.1128\/AAC.01533-06","article-title":"Concentration-dependent Mycobacterium tuberculosis killing and prevention of resistance by rifampin.","volume":"51","author":"Gumbo","year":"2007","journal-title":"Antimicrob Agents Chemother"},{"key":"R5-20230913","doi-asserted-by":"crossref","first-page":"2329","DOI":"10.1128\/AAC.00185-07","article-title":"Isoniazid bactericidal activity and resistance emergence: integrating pharmacodynamics and pharmacogenomics to predict efficacy in different ethnic populations.","volume":"51","author":"Gumbo","year":"2007","journal-title":"Antimicrob Agents Chemother"},{"key":"R6-20230913","doi-asserted-by":"crossref","first-page":"2118","DOI":"10.1128\/AAC.47.7.2118-2124.2003","article-title":"Pharmacokinetics-pharmacodynamics of rifampin in an aerosol infection model of tuberculosis.","volume":"47","author":"Jayaram","year":"2003","journal-title":"Antimicrob Agents Chemother"},{"key":"R7-20230913","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1128\/AAC.01705-12","article-title":"Contradictory results with high-dosage rifamycin in mice and humans.","volume":"57","author":"Coates","year":"2013","journal-title":"Antimicrob Agents Chemother"},{"issue":"3 Pt 1","key":"R8-20230913","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1164\/ajrccm.156.3.9609132","article-title":"The early bactericidal activity of isoniazid related to its dose size in pulmonary tuberculosis.","volume":"156","author":"Donald","year":"1997","journal-title":"Am J Respir Crit Care Med"},{"key":"R9-20230913","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1164\/rccm.200411-1557OC","article-title":"The early bactericidal activities of rifampin and rifapentine in pulmonary tuberculosis.","volume":"172","author":"Sirgel","year":"2005","journal-title":"Am J Respir Crit Care Med"},{"key":"R10-20230913","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/S1473-3099(16)30274-2","article-title":"High-dose rifampicin, moxifloxacin, and SQ109 for treating tuberculosis: a multi-arm, multi-stage randomised controlled trial.","volume":"17","author":"Boeree","year":"2017","journal-title":"Lancet Infect Dis"},{"key":"R11-20230913","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1164\/rccm.201410-1843OC","article-title":"Daily rifapentine for treatment of pulmonary tuberculosis. A randomized, dose-ranging trial.","volume":"191","author":"Dorman","year":"2015","journal-title":"Am J Respir Crit Care Med"},{"key":"R12-20230913","doi-asserted-by":"crossref","first-page":"2169","DOI":"10.2165\/00003495-200262150-00001","article-title":"Therapeutic drug monitoring in the treatment of tuberculosis.","volume":"62","author":"Peloquin","year":"2002","journal-title":"Drugs"},{"key":"R13-20230913","first-page":"1318","article-title":"Ethambutol dosage for the treatment of children: literature review and recommendations.","volume":"10","author":"Donald","year":"2006","journal-title":"Int J Tuberc Lung Dis"},{"key":"R14-20230913","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1128\/AAC.50.2.407-413.2006","article-title":"Low levels of pyrazinamide and ethambutol in children with tuberculosis and impact of age, nutritional status, and human immunodeficiency virus infection.","volume":"50","author":"Graham","year":"2006","journal-title":"Antimicrob Agents Chemother"},{"key":"R15-20230913","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1007\/BF02179950","article-title":"Ethambutol and rifampicin serum levels in children: second report on the combined administration of ethambutol and rifampicin.","volume":"149","author":"Hussels","year":"1973","journal-title":"Pneumonologie"},{"key":"R16-20230913","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1086\/598192","article-title":"Isoniazid plasma concentrations in a cohort of South African children with tuberculosis: implications for international pediatric dosing guidelines.","volume":"48","author":"McIlleron","year":"2009","journal-title":"Clin Infect Dis"},{"key":"R17-20230913","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1186\/1741-7015-7-19","article-title":"Rifampin pharmacokinetics in children, with and without human immunodeficiency virus infection, hospitalized for the management of severe forms of tuberculosis.","volume":"7","author":"Schaaf","year":"2009","journal-title":"BMC Med"},{"key":"R18-20230913","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1136\/adc.2004.052175","article-title":"Isoniazid pharmacokinetics in children treated for respiratory tuberculosis.","volume":"90","author":"Schaaf","year":"2005","journal-title":"Arch Dis Child"},{"key":"R20-20230913","doi-asserted-by":"crossref","first-page":"5560","DOI":"10.1128\/AAC.05429-11","article-title":"Pharmacokinetics of isoniazid, rifampin, and pyrazinamide in children younger than two years of age with tuberculosis: evidence for implementation of revised World Health Organization recommendations.","volume":"55","author":"Thee","year":"2011","journal-title":"Antimicrob Agents Chemother"},{"key":"R21-20230913","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1093\/jac\/dku478","article-title":"Subtherapeutic concentrations of first-line anti-TB drugs in South African children treated according to current guidelines: the PHATISA study.","volume":"70","author":"Hiruy","year":"2015","journal-title":"J Antimicrob Chemother"},{"key":"R22-20230913","doi-asserted-by":"crossref","first-page":"2171","DOI":"10.1128\/AAC.02600-15","article-title":"Pharmacokinetics of rifampin, isoniazid, pyrazinamide, and ethambutol in infants dosed according to revised WHO-recommended treatment guidelines.","volume":"60","author":"Bekker","year":"2016","journal-title":"Antimicrob Agents Chemother"},{"key":"R23-20230913","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1093\/jpids\/piv035","article-title":"Pharmacokinetics of first-line antituberculosis drugs using WHO revised dosage in children with tuberculosis with and without HIV coinfection.","volume":"5","author":"Kwara","year":"2016","journal-title":"J Pediatric Infect Dis Soc"},{"key":"R25-20230913","doi-asserted-by":"crossref","first-page":"1685","DOI":"10.1086\/599040","article-title":"Isoniazid, rifampin, ethambutol, and pyrazinamide pharmacokinetics and treatment outcomes among a predominantly HIV-infected cohort of adults with tuberculosis from Botswana.","volume":"48","author":"Chideya","year":"2009","journal-title":"Clin Infect Dis"},{"key":"R26-20230913","doi-asserted-by":"crossref","first-page":"31","DOI":"10.2217\/pgs.11.122","article-title":"Accuracy of various human NAT2 SNP genotyping panels to infer rapid, intermediate and slow acetylator phenotypes.","volume":"13","author":"Hein","year":"2012","journal-title":"Pharmacogenomics"},{"key":"R27-20230913","doi-asserted-by":"crossref","first-page":"e01701","DOI":"10.1128\/AAC.01701-16","article-title":"Pharmacokinetics of the first-line antituberculosis drugs in Ghanaian children with tuberculosis with or without HIV coinfection.","volume":"61","author":"Antwi","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"R29-20230913","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1214\/10-AOAS388","article-title":"Coordinate descent algorithms for nonconvex penalized regression, with applications to biological feature selection.","volume":"5","author":"Breheny","year":"2011","journal-title":"Ann Appl Stat"},{"key":"R30-20230913","doi-asserted-by":"crossref","first-page":"894","DOI":"10.1214\/09-AOS729","article-title":"Nearly unbaised variable selection under minimax concave penalty.","volume":"38","author":"Zhang","year":"2010","journal-title":"Ann of Statist"},{"key":"R31-20230913","doi-asserted-by":"crossref","first-page":"S63","DOI":"10.1093\/cid\/ciw471","article-title":"Drug concentration thresholds predictive of therapy failure and death in children with tuberculosis: bread crumb trails in random forests.","volume":"63","author":"Swaminathan","year":"2016","journal-title":"Clin Infect Dis"},{"key":"R33-20230913","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1007\/s40265-014-0222-8","article-title":"Therapeutic drug monitoring in the treatment of tuberculosis: an update.","volume":"74","author":"Alsultan","year":"2014","journal-title":"Drugs"},{"key":"R34-20230913","doi-asserted-by":"crossref","first-page":"3614","DOI":"10.1128\/AAC.02468-12","article-title":"Isoniazid, rifampin, and pyrazinamide plasma concentrations in relation to treatment response in Indonesian pulmonary tuberculosis patients.","volume":"57","author":"Burhan","year":"2013","journal-title":"Antimicrob Agents Chemother"},{"key":"R35-20230913","doi-asserted-by":"crossref","first-page":"1162","DOI":"10.1128\/AAC.04338-14","article-title":"Pharmacokinetics of first-line antituberculosis drugs in HIV-infected children with tuberculosis treated with intermittent regimens in India.","volume":"59","author":"Ramachandran","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"key":"R36-20230913","doi-asserted-by":"crossref","first-page":"210","DOI":"10.5588\/ijtld.14.0405","article-title":"Serum drug concentrations of INH and RMP predict 2-month sputum culture results in tuberculosis patients.","volume":"19","author":"Mah","year":"2015","journal-title":"Int J Tuberc Lung Dis"},{"key":"R37-20230913","first-page":"S231","article-title":"Studies on the treatment of tuberculosis undertaken by the British Medical Research Council tuberculosis units, 1946\u20131986, with relevant subsequent publications.","volume":"3","author":"Fox","year":"1999","journal-title":"Int J Tuberc Lung Dis"},{"key":"R38-20230913","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.1164\/rccm.200605-637OC","article-title":"Dosing schedules of 6-month regimens and relapse for pulmonary tuberculosis.","volume":"174","author":"Chang","year":"2006","journal-title":"Am J Respir Crit Care Med"},{"key":"R39-20230913","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1086\/430377","article-title":"Relapse and acquired rifampin resistance in HIV-infected patients with tuberculosis treated with rifampin- or rifabutin-based regimens in New York City, 1997-2000.","volume":"41","author":"Li","year":"2005","journal-title":"Clin Infect Dis"},{"key":"R40-20230913","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.1086\/429321","article-title":"Association between acquired rifamycin resistance and the pharmacokinetics of rifabutin and isoniazid among patients with HIV and tuberculosis.","volume":"40","author":"Weiner","year":"2005","journal-title":"Clin Infect Dis"},{"key":"R41-20230913","first-page":"5560","article-title":"The pharmacokinetics and pharmacodynamics of rifampicin in adults and children in relation to the dosage recommended for children.","volume":"55","author":"Donald","year":"2011","journal-title":"Tuberculosis (Edinb)"},{"key":"R42-20230913","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1186\/s12879-016-1790-x","article-title":"Evaluation of high-dose rifampin in patients with new, smear-positive tuberculosis (HIRIF): study protocol for a randomized controlled trial.","volume":"16","author":"Milstein","year":"2016","journal-title":"BMC Infect Dis"},{"key":"R44-20230913","first-page":"939","article-title":"The early bactericidal activity of drugs in patients with pulmonary tuberculosis.","volume":"121","author":"Jindani","year":"1980","journal-title":"Am Rev Respir Dis"},{"key":"R45-20230913","first-page":"1106","article-title":"Rifampicin serum levels in childhood tuberculosis.","volume":"13","author":"Thee","year":"2009","journal-title":"Int J Tuberc Lung Dis"}],"container-title":["Pediatric Infectious Disease Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/00006454-201801000-00007","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,13]],"date-time":"2023-09-13T18:15:25Z","timestamp":1694628925000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00006454-201801000-00007"}},"subtitle":["Adequacy of Revised Dosages of TB Drugs for Children"],"short-title":[],"issued":{"date-parts":[[2018,1]]},"references-count":40,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2018]]}},"URL":"https:\/\/doi.org\/10.1097\/inf.0000000000001687","relation":{},"ISSN":["0891-3668"],"issn-type":[{"value":"0891-3668","type":"print"}],"subject":[],"published":{"date-parts":[[2018,1]]}}}